TX-103 is under clinical development by Fuzhou Tcelltech Biological Science and Technology and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TX-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TX-103 overview
TX-103 is under development for the treatment of recurrent glioblastoma multiforme (rGBM) and malignant glioma. The therapeutic candidate is administered through parenteral route. It comprises of autologous T cells genetically engineered to express chimeric antigen receptors (CAR) targeting B7H3 expressing cancer cells.
Fuzhou Tcelltech Biological Science and Technology overview
Fuzhou Tcelltech Biological Science and Technology a healthcare provider that offers treatments to patients suffering from oncology in Malignant Glioma and other services. The company is headquartered in Fuzhou, Fujian, China.
For a complete picture of TX-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
